Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results [Yahoo! Finance]
Exagen Inc. (XGN)
Last exagen inc. earnings: 3/25 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights. Three Months Ended December 31, Year Ended December (in thousands, except ASP data) Revenue Gross margin Operating expenses Loss from operations Net loss Adjusted EBITDA Cash, cash equivalents and restricted cash Trailing-twelve-month average selling price (ASP) 2025 Highlights: Supported the diagnosis and management of care for over 137,000 patients tested by AVISE CTD. Delivered record total revenue of $66.6 million, an increase of 20% compared to 2024. Grew AVISE CTD test volume over 11% compared to 2024. Expanded AVISE CTD trailing twelve-month ASP to $441 per test, an increase of $30 per test, or 7% compared to 2024. Enhanced the AVISE CTD platform with commercial launch of novel T-Cell and seronega
Show less
Read more
Impact Snapshot
Event Time:
XGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XGN alerts
High impacting Exagen Inc. news events
Weekly update
A roundup of the hottest topics
XGN
News
- Exagen (XGN) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=XGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sell".MarketBeat
- Exagen (XGN) had its price target lowered by Canaccord Genuity Group Inc. from $15.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Exagen (XGN) had its price target lowered by Craig Hallum from $12.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Exagen (XGN) had its price target lowered by KeyCorp from $15.00 to $10.00. They now have an "overweight" rating on the stock.MarketBeat
- Avolta AG GAAP EPS of CHF 1.36, revenue of CHF 13.76B [Seeking Alpha]Seeking Alpha
XGN
Earnings
- 3/10/26 - In-Line
XGN
Sec Filings
- 3/16/26 - Form 3
- 3/16/26 - Form 4
- 3/16/26 - Form 4
- XGN's page on the SEC website